InvestSMART

Clinuvel Pharmaceuticals Limited (ASX:CUV)

ALERT: Price-sensitive ASX Announcement for CUV
Current share price for CUV : $10.260 0.48 (4.91%)+
Announcement
Release
27 Mar 2026 8:35AM
Price at Release
$9.780
Full Release
download
Summary
Clinuvel Pharmaceuticals Limited has showcased its global programs at the 2026 American Academy of Dermatology Annual Meeting in Denver. The company's focus is on the development of afamelanotide for treating vitiligo and SCENESSE®, the only FDA-approved treatment for erythropoietic protoporphyria (EPP). A significant highlight is the unveiling of the Vitiligo Visual Algorithm (VVA), an AI tool designed to objectively evaluate clinical images in vitiligo treatments. The VVA aims to set a new standard in clinical assessments and is integrated into Clinuvel's ongoing and upcoming vitiligo studies. Additionally, the reimagined Pavilion of Photomedicine aims to engage audiences and differentiate Clinuvel’s approach to drug development.
Key Points
  • Clinuvel's programs highlighted at 2026 AAD Meeting
  • Focus on afamelanotide for vitiligo and SCENESSE® for EPP
  • Introduction of the Vitiligo Visual Algorithm (VVA)
  • VVA uses AI for clinical image assessment
  • Reimagined Pavilion of Photomedicine showcased
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.